Hormone Replacement Therapy and Life Expectancy After Prophylactic Oophorectomy in Women With BRCA1/2 Mutations: A Decision Analysis
- 15 March 2004
- journal article
- breast cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (6) , 1045-1054
- https://doi.org/10.1200/jco.2004.06.090
Abstract
Purpose The decision about prophylactic oophorectomy is difficult for many premenopausal women with BRCA1/2 mutations because of concerns and controversy about the use of hormone replacement therap...Keywords
This publication has 65 references indexed in Scilit:
- Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions: Recommendations and RationaleAnnals of Internal Medicine, 2002
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Prophylactic Oophorectomy in Carriers ofBRCA1orBRCA2MutationsNew England Journal of Medicine, 2002
- Hormone Replacement Therapy and Cardiovascular DiseaseCirculation, 2001
- Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation CarriersJNCI Journal of the National Cancer Institute, 1999
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997
- Patient-Specific Decisions About Hormone Replacement Therapy in Postmenopausal WomenPublished by American Medical Association (AMA) ,1997
- Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women.American Journal of Public Health, 1995
- Unusual case of Smith‐Lemli‐Opitz syndrome “type II”American Journal of Medical Genetics, 1995